Activating mutations in KIT are responsible for most of the gastro-intestinal stromal tumors (GIST) and many of the current therapies that target KIT and PDGFRA proteins result in the onset of resistance. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.